Novavax (NVAX) Common Equity (2010 - 2026)

Novavax's Common Equity history runs 17 years deep, the most recent figure standing at -$144.8 million for Q1 2026.

• In Q1 2026, Common Equity fell 91.38% year-over-year to -$144.8 million; the TTM figure through Mar 2026 stood at -$144.8 million (down 91.38% YoY), while the FY2025 annual figure was -$127.8 million, up 79.52% from the prior year.
• Common Equity was -$144.8 million for Q1 2026 at Novavax, down from -$127.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $65.3 million in Q1 2022 to a low of -$895.6 million in Q1 2023.
• Historically, Common Equity has averaged -$442.0 million across 5 years, with a median of -$526.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 1470.98% in 2023, then surged 108.72% in 2025.
• A 5-year view of Common Equity shows it stood at -$634.1 million in 2022, then declined by 13.07% to -$716.9 million in 2023, then increased by 12.98% to -$623.8 million in 2024, then soared by 79.52% to -$127.8 million in 2025, then decreased by 13.31% to -$144.8 million in 2026.
• The last three Common Equity figures came in at -$144.8 million (Q1 2026), -$127.8 million (Q4 2025), and -$156.7 million (Q3 2025), per Business Quant data.